PMV Pharmaceuticals Announces Participation at the Bank of America Securities 2021 Napa Biopharma Virtual Conference
PMV Pharmaceuticals (Nasdaq: PMVP) announced its participation in the Bank of America Securities 2021 Napa Biopharma Virtual Conference, where David H. Mack, Ph.D., President & CEO, will present on June 14, 2021, at 2:30 PM ET. The company specializes in developing tumor-agnostic therapies targeting p53 mutations, prevalent in nearly half of all cancers. PMV Pharma combines over 40 years of p53 biology expertise with a strong pharmaceutical development focus. For more information, visit pmvpharma.com.
- Participation in notable Bank of America Securities conference enhances visibility.
- Focus on p53 mutations aligns with significant cancer treatment opportunities.
- None.
CRANBURY, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., President & Chief Executive Officer, will present at the Bank of America Securities 2021 Napa Biopharma Virtual Conference on Monday, June 14th.
Details on the presentation can be found below.
Bank of America Securities 2021 Napa Biopharma Virtual Conference | |
Date: | Monday, June 14, 2021 |
Time: | 2:30 PM ET |
About PMV Pharma
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma is headquartered in Cranbury, New Jersey. For more information, please visit www.pmvpharma.com.
Contact
For Investors & Media:
Winston Kung
Chief Financial Officer
investors@pmvpharma.com
FAQ
What conference is PMV Pharmaceuticals participating in?
When will David H. Mack present at the conference?
What is the focus of PMV Pharmaceuticals' therapies?